Indolocarbazole derivatives to treat a pathological condition of

Details Indolocarbazole derivatives to treat a pathological condition of Indolocarbazole derivatives to treat a pathological condition of

1995-06-05

1997-08-05

Raymond, Richard L.

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

548416, C07D49822

Patent

active

056544278

ABSTRACT:
The invention features a method of treating a pathological condition of the prostate gland, e.g., benign prostatic hypertrophy or prostate cancer, in a mammal, said method comprising administering to said mammal a therapeutic amount of the indolocarbazole compound K-252a or a preferred derivative thereof. The invention also includes novel derivatives of K-252a.

REFERENCES:
patent: 4877776 (1989-10-01), Murakata et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5043335 (1991-08-01), Kleinschoth et al.
patent: 5073633 (1991-12-01), Schroeder et al.
patent: 5461146 (1995-10-01), Lewis et al.
Akinaga et al., "Antitumor Effect of KT6124, a Novel Derivative of Protein Kinase Inhibitor K-252A, and its Mechanism of Action," Cancer Chemother. Pharmacol. 29:266-272 (1992).
Battistone et al., "1-Dehydro-melengestrol acetate inhibits the growth and protein kinase C activity of androgen-independent Dunning rat prostatic tumors," Cancer Chemother. Pharmacol 31:407-411 (1993).
Berg et al., "K-252a Inhibits Nerve Growth Factor-Induced trk Proto-Oncogene Tyrosine Phosphorylation and Kinase Activity," J. Biological Chem. 267:13-16 (1992).
Bozyczko-Coyne et al., "A Rapid Fluorometric Assay to Measure Neuronal Survival in Vitro," Journal of Neuroscience Methods, 50:205-216 (1993).
Brocker et al., "Nerve Growth and Expression of Receptors for Nerve Growth Factor in Tumors of Melanocyte Origin," J. Investigative Dermatology 96:662-665 (1991).
Cunha et al., "Normal and Abnormal Development of the Male Urogenital Tract," J. Andrology, 13:465-475 (1992).
Djakiew et al., "Regulating of Growth by a Nerve Growth Factor-Like Protein Which Modules Paracrine Interactions Between a Neoplastic Epithelial Cell Line . . . ," Cancer Research 51:3304-3310 (1991).
Eisenberger et al., "Suramin, An Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial," J. of Nat. Cancer Institute 85:611-621 (1993).
Elliott et al., "K252a is a Potent and Selective Inhibitor of Phosphorylase Kinase," Biochemical and Biophysical Research Communications 171:148-154 (1990).
Hashimoto et al., "Blockage of Nerve Growth Factor Action in PC12h Cells by Staurosporine, A Potent Protein Kinase Inhibitor," J. Neurochemistry 53:1675-1685 (1989).
Hempstead et al., "Overexpression of the trk Tyrosine Kinase Rapidly Accelerates Nerve Growth Factor-Induced Differentiation," Neuron 9:883-896 (1992).
Hirata et al., Chemical Abstracts, vol. 111, No. 21, Issued Nov. 20, 1989, Abstract 194456g.
Hughes et al., "Synthesis of the Indolo[2,3-A]Carbazole Natural Products Staurosporinone and Arcyiaflavin B," J. Chem. Soc. Perkin Trans. 1:2475-2480 (1990).
Ichikawa et al., "The Antitumor Effects of Quinoline-3-Carboxamide Linomide on Dunning R-3327 Rat Prostatic Cancers," Cancer Research 52:3022-3028 (1992).
Issacs et al., "Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and Their Use in Developing Methods for Predicting . . . " The Prostate 9:261-281 (1986).
Mac Grogan et al., "Expression of Nerve Growth Factor and Nerve Growth Factor Receptor Genes in Human Tissues and in Prostatic Adenocarcinoma Cell Lines," J. Neurochemistry, 59:1381-1390 (1992).
Morton et al., "Differential Effects of Growth Factor Antagonists on Neoplastic and Normal Prostatic Cells," The Prostate 17:327-336 (1990).
Nakagawa et al., "Association Between High Levels of Expression of the TRK Gene and Favorable Outcome in Human Neuroblastoma," New England J. Medicine 328:847-854 (1993).
Nye et al., "K-252a and Staurosporine Selectively Block Autophosphorylation of Neurotrophin Rectors and Neurotrophin-Mediated Responses," Molecular Biology of the Cell 3:677-686 (1992).
Tapley et al., "K252A is a Selective Inhibitor of the Tyrosine Protein Kinase Activity of the trk Family of Oncogenes and Neurotrophin Receptors," Oncogene 7:371-381 (1992).
Tishler et al., Chemical Abstracts, vol. 113, No. 21, Issued Nov. 19, 1990.

Affiliated with

Also associated with

Rating

Indolocarbazole derivatives to treat a pathological condition of does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indolocarbazole derivatives to treat a pathological condition of, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolocarbazole derivatives to treat a pathological condition of will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1075966